EXPLORE THE SCIENCE
TL;DR: In a small UK trial, 60 people with depression that hadn’t responded to standard treatment got either one 25-mg dose of psilocybin or a placebo, plus therapy support. Three weeks later, 13 of 30 people in the psilocybin group had responded, versus 1 of…
Read article
TL;DR: A 2026 study in Neuropsychopharmacology found that 30 mg 2C-B produced acute subjective effects in healthy adults that were similar in overall intensity to 125 mg MDMA, shorter and less distressing than 25 mg psilocybin, and less cardiovascularly stimul…
Read article
TL;DR: A 2026 exploratory study in Translational Psychiatry found blood DNA methylation changes after 25 mg psilocybin in detoxified alcohol use disorder patients, including findings near TLE4 and RASGRP4, but the small trial did not establish a definitive AUD…
Read article
TL;DR: A 2026 trial in Journal of Psychopharmacology found that repeated supervised psilocybin sessions reduced Yale-Brown Obsessive Compulsive Scale (YBOCS) scores, a standard measure of obsession and compulsion severity, in 15 adults with OCD. Key Findings 7…
Read article
TL;DR: A 2026 Scientific Reports study of 6,805 English-language media reports found that psychedelic-treatment coverage for depression and PTSD used more positive tone than antidepressant coverage, while antidepressant coverage used more risk and negative-emo…
Read article
TL;DR: A 2026 randomized clinical trial in JAMA Network Open found that one supervised 30 mg/70 kg psilocybin dose plus cognitive behavioral therapy produced 40.5% six-month smoking abstinence versus 10.0% with a nicotine patch plus the same therapy. Key Findi…
Read article
TL;DR: A 2026 mouse preprint in bioRxiv found that psilocybin reduced firing in somatostatin (SST) interneurons, inhibitory cortical cells that gate dendritic input, while increasing parvalbumin (PV) interneuron firing in the medial frontal cortex. Key Finding…
Read article
TL;DR: A 2026 exploratory study in Nature Communications found that a first 25 mg psilocybin dose in 28 psychedelic-naive adults increased electroencephalography (EEG), a scalp recording of brain electrical activity, entropy during the acute session and that e…
Read article
Fluorinated Psilocin: The Sub-Hallucinogenic Breakthrough TL;DR: Chemists designed a new psilocin derivative with fluorine modifications that induces sub-hallucinogenic effects in mice, sidestepping the acute psychological effects of classic psychedelics while…
Read article
Major depressive disorder (MDD) is a global health crisis affecting over 300 million people. While available antidepressants help some patients, treatment is far from satisfactory for many. Exciting research into rapid-acting agents like ketamine and psilocybi…
Read article